Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Krishna Vaddi D.V.M., Ph.D. | Founder, CEO & Director | 905.92k | -- | 1966 |
| Dr. Edna Huang M.D. | President & Chief Medical Officer | 865.63k | -- | 1973 |
| Mr. Bryant David Lim J.D. | Interim CFO, Chief Legal Officer & Corporate Secretary | 586.42k | -- | 1971 |
| Ms. Aimee Crombie Ph.D. | Senior VP and Head of Strategic Planning & Operations | -- | -- | -- |
| Dr. Madhu Pudipeddi Ph.D. | Senior Vice President of Technical Operations | -- | -- | -- |
| Dr. Peggy A. Scherle Ph.D. | Chief Scientific Officer | 868.62k | -- | 1962 |
| Ms. Lindsey Trickett | Vice President of Investor Relations | -- | -- | -- |
| Ms. Michele Porreca M.B.A. | Chief People Officer | -- | -- | -- |
| Dr. Andrew P. Combs Ph.D. | Executive VP & Chief Chemistry Officer | 562.46k | -- | 1966 |
| Mr. Naveen Babbar Ph.D. | Senior Vice President of Translation Medicine | -- | -- | -- |
Prelude Therapeutics Incorporated
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 128
Description
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Corporate Governance
Upcoming Events
February 13, 2025 at 10:59 AM UTC - February 17, 2025 at 12:00 PM UTC
Prelude Therapeutics Incorporated Earnings Date
Recent Events
June 6, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission